Identification of an Immune-Related Gene Signature Based on Immunogenomic Landscape Analysis to Predict the Prognosis of Adult Acute Myeloid Leukemia Patients

Frontiers in Oncology
Ruiqi ZhuYu Hu


Acute myeloid leukemia (AML) is a hematopoietic malignancy characterized by highly heterogeneous molecular lesions and cytogenetic abnormalities. Immune disorders in AML and impaired immune cell function have been found to be associated with abnormal karyotypes in AML patients. Immunotherapy has become an alternative therapeutic method that can improve the outcomes of AML patients. For solid tumors, the expression patterns of genes associated with the immune microenvironment provide valuable prognostic information. However, the prognostic roles of immune genes in AML have not been studied as yet. In this study, we identified 136 immune-related genes associated with overall survival in AML patients through a univariate Cox regression analysis using data from TCGA-AML and GTEx datasets. Next, we selected 24 hub genes from among the 136 genes based on the PPI network analysis. The 24 immune-related hub genes further underwent multivariate Cox regression analysis and LASSO regression analysis. Finally, a 6 immune-related gene signature was constructed to predict the prognosis of AML patients. The function of the hub IRGs and the relationships between hub IRGs and transcriptional factors were investigated. We found that higher level...Continue Reading


Feb 3, 2004·Proceedings of the National Academy of Sciences of the United States of America·Nikolai N KhodarevRalph R Weichselbaum
Apr 28, 2009·BMC Medical Genomics·Hideaki MizunoAkinori Sarai
Jun 10, 2010·Clinical and Experimental Immunology·A J Barrett, K Le Blanc
Dec 29, 2013·Biochemical and Biophysical Research Communications·Min Soo KimWook Jin
Jun 25, 2014·Leukemia Research·Felix S LichteneggerMarion Subklewe
Dec 2, 2014·Pediatric Clinics of North America·Stacy L Cooper, Patrick A Brown
Jun 4, 2015·Expert Opinion on Biological Therapy·Alison SehgalMichael Boyiadzis
Jul 21, 2015·Nature Medicine·Andrew J GentlesAsh A Alizadeh
Sep 2, 2015·The Journal of Clinical Investigation·Yiping Yang
Jun 2, 2016·Critical Reviews in Oncology/hematology·Rebecca AustinSteven W Lane
Sep 15, 2016·Science Signaling·Laure DavidJean-Sébastien Hoffmann
Jun 27, 2017·The Journal of Clinical Investigation·Mark AyersTerrill K McClanahan
Mar 22, 2018·The New England Journal of Medicine·Robert J MotzerUNKNOWN CheckMate 214 Investigators
Apr 19, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David TamboreroAbel Gonzalez-Perez
Jun 29, 2018·Frontiers in Oncology·Adam J Lamble, Evan F Lind
Aug 23, 2018·The New England Journal of Medicine·Hussein A TawbiKim Margolin
Nov 28, 2018·Biomedicines·Jan Davidson-MoncadaSergio Rutella
Dec 18, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick A OttJared K Lunceford
May 9, 2019·Future Oncology·Martin ReckKenneth J O'Byrne
Oct 28, 2019·Leukemia·Abdelrahman H ElsayedJatinder K Lamba

❮ Previous
Next ❯

Datasets Mentioned


Software Mentioned

R Bioconductor

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.